Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:

A is ~~selected from the group consisting of:~~

phenyl~~, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl~~;

B is ~~selected from the group consisting of:~~

phenyl~~, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl~~;

Het-CH_2-R^3 is ~~selected from the group consisting of:~~



;

M has the formula:



wherein

L^1 is a bond or $C_{1\text{-}6}$ alkyl optionally substituted with one or more R^4 groups;

L^2 is a bond or $C_{1\text{-}6}$ alkyl optionally substituted with one or more R^4 groups;

Q is selected from the group consisting of:

a) H, b) -NR^4R^4, c) -OR^4, and d) $C_{1\text{-}6}$ alkyl optionally substituted with one or more R^4 groups; and

W is selected from the group consisting of O and S;

X is selected from the group consisting of:

a) $-NR^4-$, b) $-NR^4NR^4-$, and c) -S-;

L is C_{1-6} alkyl optionally substituted with one or more R^4 groups;

R^1, at each occurrence, independently is selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) $-CF_3$, f) $-OR^7$, g) -CN, h) $-NO_2$, i) $-NR^7R^7$, j) $-C(O)R^7$, k) $-C(O)OR^7$, l) $-OC(O)R^7$, m) $-C(O)NR^7R^7$, n) $-NR^7C(O)R^7$, o) $-OC(O)NR^7R^7$, p) $-NR^7C(O)OR^7$, q) $-NR^7C(O)NR^7R^7$, r) $-C(S)R^7$, s) $-C(S)OR^7$, t) $-OC(S)R^7$, u) $-C(S)NR^7R^7$, v) $-NR^7C(S)R^7$, w) $-OC(S)NR^7R^7$, x) $-NR^7C(S)OR^7$, y) $-NR^7C(S)NR^7R^7$, z) $-C(NR^7)R^7$, aa) $-C(NR^7)OR^7$, bb) $-OC(NR^7)R^7$, cc) $-C(NR^7)NR^7R^7$, dd) $-NR^7C(NR^7)R^7$, ee) $-OC(NR^7)NR^7R^7$, ff) $-NR^7C(NR^7)OR^7$, gg) $-NR^7C(NR^7)NR^7R^7$, hh) $-S(O)_pR^7$, ii) $-SO_2NR^7R^7$, and jj) R^7;

R^2, at each occurrence, independently is selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) $-CF_3$, f) $-OR^7$, g) -CN, h) $-NO_2$, i) $-NR^7R^7$, j) $-C(O)R^7$, k) $-C(O)OR^7$, l) $-OC(O)R^7$, m) $-C(O)NR^7R^7$, n) $-NR^7C(O)R^7$, o) $-OC(O)NR^7R^7$, p) $-NR^7C(O)OR^7$, q) $-NR^7C(O)NR^7R^7$, r) $-C(S)R^7$, s) $-C(S)OR^7$, t) $-OC(S)R^7$, u) $-C(S)NR^7R^7$, v) $-NR^7C(S)R^7$, w) $-OC(S)NR^7R^7$, x) $-NR^7C(S)OR^7$, y) $-NR^7C(S)NR^7R^7$, z) $-C(NR^7)R^7$, aa) $-C(NR^7)OR^7$, bb) $-OC(NR^7)R^7$, cc) $-C(NR^7)NR^7R^7$, dd) $-NR^7C(NR^7)R^7$, ee) $-OC(NR^7)NR^7R^7$, ff) $-NR^7C(NR^7)OR^7$, gg) $-NR^7C(NR^7)NR^7R^7$, hh) $-S(O)_pR^7$, ii) $-SO_2NR^7R^7$, and jj) R^7;

R^3 is selected from the group consisting of:

a) $-OR^7$, b) $-NR^7R^7$, c) $-C(O)R^7$, d) $-C(O)OR^7$, e) $-OC(O)R^7$, f) $-C(O)NR^7R^7$, g) $-NR^7C(O)R^7$, h) $-OC(O)NR^7R^7$, i) $-NR^7C(O)OR^7$, j) $-NR^7C(O)NR^7R^7$, k) $-C(S)R^7$, l) $-C(S)OR^7$, m) $-OC(S)R^7$, n) $-C(S)NR^7R^7$, o) $-NR^7C(S)R^7$, p) $-OC(S)NR^7R^7$, q) $-NR^7C(S)OR^7$, r) $-NR^7C(S)NR^7R^7$, s) $-C(NR^7)R^7$, t) $-C(NR^7)OR^7$, u) $-OC(NR^7)R^7$, v) $-C(NR^7)NR^7R^7$, w) $-NR^7C(NR^7)R^7$,

x) -OC(NR^7)NR^{7}R^7, y) –NR^{7}C(NR^7)OR^7, z) –NR^{7}C(NR^7)NR^{7}R^7, aa) -S(O)$_p$R^7,
bb) -SO$_2$NR^{7}R^7, and cc) R^7;

R^4, at each occurrence, independently is selected from the group consisting of:

a) H, b) =O, c) =S, d) =NR^5, e) =NOR^5, f) =N-NR^{5}R^5, g) –OR^5, h) -NO$_2$, i) -NR^{5}R^5,
j) -C(O)R^5, k) -C(O)OR^5, l) -OC(O)R^5, m) -C(O)NR^{5}R^5, n) -NR^{5}C(O)R^5,
o) -OC(O)NR^{5}R^5, p) -NR^{5}C(O)OR^5, q) -NR^{5}C(O)NR^{5}R^5, r) -C(S)R^5,
s) -C(S)OR^5, t) -OC(S)R^5, u) -C(S)NR^{5}R^5, v) -NR^{5}C(S)R^5, w) -OC(S)NR^{5}R^5,
x) –NR^{5}C(S)OR^5, y) -NR^{5}C(S)NR^{5}R^5, z) -C(NR^5)R^5, aa) -C(NR^5)OR^5,
bb) -OC(NR^5)R^5, cc) -C(NR^5)NR^{5}R^5, dd) -NR^{5}C(NR^5)R^5, ee) -OC(NR^5)NR^{5}R^5,
ff) -NR^{5}C(NR^5)OR^5, gg) -NR^{5}C(NR^5)NR^{5}R^5, hh) -S(O)$_p$R^5, and ii) R^5;

R^5, at each occurrence, independently is selected from the group consisting of:

a) H, b) C$_{1\text{-}6}$ alkyl, c) -C(O)-C$_{1\text{-}6}$ alkyl, and d) -C(O)O-C$_{1\text{-}6}$ alkyl,
wherein any of b) – d) optionally is substituted with one or more R^6 groups;

R^6, at each occurrence, independently is selected from the group consisting of:

a) –OH, b) –OC$_{1\text{-}6}$ alkyl, c) -SH, d) -NO$_2$, e) –NH$_2$, f) -NHC$_{1\text{-}6}$ alkyl,
g) -N(C$_{1\text{-}6}$ alkyl)$_2$, h) –C(O)H, i) –C(O)OH, j) -C(O)C$_{1\text{-}6}$ alkyl,
k) -OC(O)C$_{1\text{-}6}$ alkyl, l) -C(O)OC$_{1\text{-}6}$ alkyl, m) -C(O)NH$_2$, n) –C(O)NHC$_{1\text{-}6}$ alkyl,
o) -C(O)N(C$_{1\text{-}6}$ alkyl)$_2$, p) -NHC(O)C$_{1\text{-}6}$ alkyl, and q) -S(O)$_p$C$_{1\text{-}6}$ alkyl;

R^7, at each occurrence, independently is selected from the group consisting of:

a) H, b) C$_{1\text{-}6}$ alkyl, c) C$_{2\text{-}6}$ alkenyl, d) C$_{2\text{-}6}$ alkynyl, e) C$_{3\text{-}14}$ saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) -C(O)-C$_{1\text{-}6}$ alkyl, h) -C(O)-C$_{2\text{-}6}$ alkenyl,
i) –C(O)-C$_{2\text{-}6}$ alkynyl, j) -C(O)-C$_{3\text{-}14}$ saturated, unsaturated, or aromatic carbocycle,
k) -C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) -C(O)O-C$_{1\text{-}6}$ alkyl, m) -C(O)O-C$_{2\text{-}6}$ alkenyl,
n) –C(O)O-C$_{2\text{-}6}$ alkynyl, o) -C(O)O-C$_{3\text{-}14}$ saturated, unsaturated, or aromatic carbocycle, and p) -C(O)O-3-14 membered saturated, unsaturated, or aromatic

heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of b) – p) optionally is substituted with one or more R^8 groups;

R^8, at each occurrence, is independently selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) =O, f) =S, g) =NR^9, h) =NOR^9, i) =N-NR^9R^9, j) -CF_3, k) –OR^9, l) -CN, m) -NO_2, n) –NR^9R^9, o) -$C(O)R^9$, p) -$C(O)OR^9$, q) -$OC(O)R^9$, r) -$C(O)NR^9R^9$, s) –$NR^9C(O)R^9$, t) -$OC(O)NR^9R^9$, u) –$NR^9C(O)OR^9$, v) -$NR^9C(O)NR^9R^9$, w) -$C(S)R^9$, x) -$C(S)OR^9$, y) -$OC(S)R^9$, z) -$C(S)NR^9R^9$, aa) -$NR^9C(S)R^9$, bb) -$OC(S)NR^9R^9$, cc) –$NR^9C(S)OR^9$, dd) –$NR^9C(S)NR^9R^9$, ee) -$C(NR^9)R^9$, ff) -$C(NR^9)OR^9$, gg) -$OC(NR^9)R^9$, hh) -$C(NR^9)NR^9R^9$, ii) -$NR^9C(NR^9)R^9$, jj) -$OC(NR^9)NR^9R^9$, kk) –$NR^9C(NR^9)OR^9$, ll) -$NR^9C(NR^9)NR^9R^9$, mm) -$S(O)_pR^9$, nn) -$SO_2NR^9R^9$, and oo) R^9;

R^9, at each occurrence, independently is selected from the group consisting of:

a) H, b) $C_{1\text{-}6}$ alkyl, c) $C_{2\text{-}6}$ alkenyl, d) $C_{2\text{-}6}$ alkynyl, e) $C_{3\text{-}14}$ saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) -C(O)-$C_{1\text{-}6}$ alkyl, h) -C(O)-$C_{2\text{-}6}$ alkenyl, i) –C(O)-$C_{2\text{-}6}$ alkynyl, j) -C(O)-$C_{3\text{-}14}$ saturated, unsaturated, or aromatic carbocycle, k) -C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) -C(O)O-$C_{1\text{-}6}$ alkyl, m) -C(O)O-$C_{2\text{-}6}$ alkenyl, n) –C(O)O-$C_{2\text{-}6}$ alkynyl, o) -C(O)O-$C_{3\text{-}14}$ saturated, unsaturated, or aromatic carbocycle, and p) -C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of b) – p) optionally is substituted with one or more moieties selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) -CF_3, f) –OH, g) –$OC_{1\text{-}6}$ alkyl, h) -SH, i) -$SC_{1\text{-}6}$ alkyl, j) -CN, k) -NO_2, l) –NH_2, m) –$NHC_{1\text{-}6}$ alkyl, n) -$N(C_{1\text{-}6}$ alkyl$)_2$, o) -$C(O)C_{1\text{-}6}$ alkyl, p) -$OC(O)C_{1\text{-}6}$ alkyl,

q) -C(O)OC$_{1-6}$ alkyl, r) -C(O)NH$_2$, s) –C(O)NHC$_{1-6}$ alkyl,

t) -C(O)N(C$_{1-6}$ alkyl)$_2$, u) -NHC(O)C$_{1-6}$ alkyl, v) -SO$_2$NH$_2$-,

w) -SO$_2$NHC$_{1-6}$ alkyl, x) -SO$_2$N(C$_{1-6}$ alkyl)$_2$, and

y) -S(O)$_p$C$_{1-6}$ alkyl;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4; and

p, at each occurrence, independently is 0, 1, or 2,

and wherein the compound does not have the formula selected from the group consisting of:



,



, and



.

2. (Canceled)

3. (Previously Presented) The compound according to claim 1 having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, B, L, M, R^1, R^2, R^3, X, m, and n are defined as described in claim 1.

4. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein

~~A is selected from the group consisting of phenyl and pyridyl;~~

~~B is selected from the group consisting of phenyl and pyridyl;~~

m is 0, 1, or 2; and

n is 0, 1, or 2.

5. (Canceled)

6. (Currently Amended) The compound according to claim [[5]]1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A-B is:



,

wherein A is defined as described in claim 1.

7. (Currently Amended) The compound according to claim [[5]]1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A-B is:



,

wherein A is defined as described in claim 1.

8. (Canceled)

9. (Canceled)

10. (Previously Presented) The compound according to claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R^3 is $-NHC(O)R^7$.

11. (Previously Presented) The compound according to claim 10, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R^3 is $-NHC(O)CH_3$.

12. (Previously Presented) The compound according to claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R^3 is:



13. (Previously Presented) The compound according to claim 1, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, B, L, M, R^1, R^2, X, m, and n are defined as described in claim 1.

14. (Previously Presented) The compound according to claim 1, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, R^3, X, and m are defined as described in claim 1.

15. (Original) The compound according to claim 14, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, X, and m are defined as described in claim 1.

16. (Original) The compound according to claim 14, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

17. (Original) The compound according to claim 16, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

18. (Canceled)

19. (Canceled)

20. (Previously Presented) The compound according to claim 1, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, R^3, X, and m are defined as described in claim 1.

21. (Original) The compound according to claim 20, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, X, and m are defined as described in claim 1.

22. (Original) The compound according to claim 20, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

23. (Original) The compound according to claim 22, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

24. (Canceled)

25. (Canceled)

26. (Previously Presented) The compound according to claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein M is:



and R^4, at each occurrence, independently is defined as described in claim 1.

27. (Previously Presented) The compound according to claim 26, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein M is:



and R^4 is defined as described in claim 1.

28. (Previously Presented) The compound according to claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein M is:



and R^4, at each occurrence, independently is defined as described in claim 1.

29. (Previously Presented) The compound according to claim 28, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein M is:



and R^4 is defined as described in claim 1.

30. (Previously Presented) The compound according to claims 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein X is –NH-.

31. (Previously Presented) The compound according to claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein X is:



32. (Currently Amended) A compound ~~having the structure corresponding to any one of the structures listed in Table 1,~~ selected from compounds 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, and 184, or a pharmaceutically acceptable salt, ester, or prodrug thereof.

33. (Previously Presented) A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier.

34.-43. (Canceled).

44. (Previously Presented) A medical device containing one or more compounds according to claim 1.

45. (Original) The medical device according to claim 44, wherein the device is a stent.